Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 2,830 | 169 | 741 | 965 | 311 |
| Gross Profit | 2,830 | 169 | 741 | 965 | 311 |
| Operating Expenses | 29,759 | 21,983 | 29,102 | 19,532 | 19,554 |
| Operating Income | -26,929 | -21,814 | -28,361 | -18,567 | -19,243 |
| Other Income | 4,206 | 1,963 | -3,120 | 2,889 | 62,374 |
| Pre-tax Income | -22,723 | -19,851 | -31,481 | -15,678 | 43,131 |
| Income Tax | 317 | 30 | 56 | 185 | 43 |
| Net Income Continuous | -23,040 | -19,881 | -31,537 | -15,863 | 43,088 |
| Net Income | $-23,040 | $-19,881 | $-31,537 | $-15,863 | $43,088 |
| EPS Basic Total Ops | -2.21 | -3.00 | -3.04 | -1.53 | 5.12 |
| EPS Basic Continuous Ops | -2.21 | -3.00 | -3.04 | -1.53 | 5.12 |
| EPS Diluted Total Ops | -2.21 | 4.23 | -3.04 | -1.53 | -2.11 |
| EPS Diluted Continuous Ops | -2.21 | -2.82 | -3.04 | -1.53 | 4.95 |
| EPS Diluted Before Non-Recurring Items | N/A | -1.91 | -3.04 | -1.53 | -2.11 |
| EBITDA(a) | $-27,002 | $-23,384 | $-28,373 | $-18,300 | $-19,186 |